PHIO Phio Pharmaceuticals Corp
17,265
$0.7045
$0.0655
(8.51%)
| Watchers | 17,265 |
| 52-Wk Low | $0.50 |
| 52-Wk High | $6.85 |
| Market Cap | $3.23M |
| Volume | 53,725.00 |
| 52-Wk High | $6.85 |
| 52-Wk Low | $0.50 |
Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?Benzinga • 20 days ago
Phio Pharmaceuticals unveils findings on PH-762, a promising candidate for cancer therapy. Discover its rapid cell uptake and tumor-inhibiting potential.
read more...
Share to Feed
Program will be airing on PBS with Dennis Quaid in April It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Four sites across the country participating in clinical trial for lead product candidate PH-762 Two patients have already completed treatment New patent granted for skin related treatments...
Poster will be unveiled this week at the Immunotherapy Conference in MunichMARLBOROUGH, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...
--Four sites across the U.S. are now engaged in the Phase1b studyMARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology...
Phio's Compound RXI-185 and RXI-231 designed to treat photo-aging and hyperpigmentationMARLBOROUGH, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical...
--New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...